Aspen Neuroscience, Inc. ASPE
IPO
NASDAQ
| 06/30/2026 | |||||
|---|---|---|---|---|---|
| Net Income | -9.18% | ||||
| Total Depreciation and Amortization | 3.65% | ||||
| Total Amortization of Deferred Charges | -- | ||||
| Total Other Non-Cash Items | 32.62% | ||||
| Change in Net Operating Assets | 132.19% | ||||
| Cash from Operations | 12.03% | ||||
| Capital Expenditure | 4.25% | ||||
| Sale of Property, Plant, and Equipment | -- | ||||
| Cash Acquisitions | -- | ||||
| Divestitures | -- | ||||
| Other Investing Activities | 151.61% | ||||
| Cash from Investing | 145.49% | ||||
| Total Debt Issued | -- | ||||
| Total Debt Repaid | -- | ||||
| Issuance of Common Stock | -65.93% | ||||
| Repurchase of Common Stock | -- | ||||
| Issuance of Preferred Stock | -- | ||||
| Repurchase of Preferred Stock | -- | ||||
| Total Dividends Paid | -- | ||||
| Other Financing Activities | -- | ||||
| Cash from Financing | -960.44% | ||||
| Foreign Exchange rate Adjustments | -- | ||||
| Miscellaneous Cash Flow Adjustments | -- | ||||
| Net Change in Cash | 106.81% | ||||